Video

Kim Smith-Whitley, MD: Voxelotor and Sickle Cell Disease

Author(s):

Kim Smith-Whitley, MD, discussed her research on voxelotor as treatment for children with sickle cell disease.

In an interview with HCPLive®, Kim Smith-Whitley, MD, Executive Vice President and Head of Research & Development, Global Blood Therapeutics (GBT), spoke passionately about her research on voxelotor (Oxbryta) for children with sickle cell disease.

“We have really started to just explore the possibilities for intervening and improving the health of those with sickle cell,” she said.

GBT announced that the US Food and Drug Administration (FDA) accepted the company’s supplemental New Drug Application (sNDA) for filing and review. The company is seeking accelerated approval for voxelotor for the treatment of sickle cell disease in children aged 4-11.

Smith-Whitley conducted a study that supported the supplemental application. The results found that the effectiveness and the safety profile of voxelotor as treatment for sickle cell disease is consistent in children aged 4-11, as already observed in adolescents and adults.

As a world-renowned hematologist with more than 30 years experience, Smith-Whitley’s research has focused on sickle cell disease, specifically pulmonary complications, transfusion-related complications and health care utilization.

According to Smith-Whitley, while much progress has been made there’s still a lot of work to do regarding sickle cell treatment.

“One of the reasons I’m so passionate about it is because this community is so overlooked,” Smith-Whitley said.

The study, “Safety and Efficacy of Voxelotor in Pediatric Patients With Sickle Cell Disease Aged 4-11 Years: Results From the Phase 2a HOPE-KIDS 1 Study”, was presented at European Hematology Association Congress 2021.

Related Videos
Françoise Bernaudin, MD: A Decade of Follow-up Reveals allo-SCT Superiority Over SOC for Sickle Cell Anemia
Achieving Quick Responses in Sickle Cell Anemia With Early, Appropriate Hydroxyurea Dosing, with Abena Appiah-Kubi, MD, MPH
Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Christian Sadaka, MD: Significant Increase in Pediatric Gastroparesis Hospital Admissions After COVID-19
Christine N. Kay, MD | Image Credit: Atsena Therapeutics
Christine N. Kay, MD: Interim Data on ATSN-201 Shows Promise for XLRS | Image Credit: Vitreo Retinal Associates
Roger A. Goldberg, MD: Pooled Visual Function Data of NT-501 for MacTel | Image Credit: Bay Area Retina Associates
Developing Risk Assessment Tools for Viruses in School
© 2024 MJH Life Sciences

All rights reserved.